We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Metabolic Disturbances Characterize Patients with Idiopathic Intracranial Hypertension

By LabMedica International staff writers
Posted on 09 Sep 2022

Individuals suffering from idiopathic intracranial hypertension are distinguishable by irregularities in the distribution of metabolites that can be detected in CSF, serum, and urine. More...

Idiopathic intracranial hypertension (IIH) is a condition characterized by increased pressure around the brain that appears without a detectable cause. The main symptoms are headache, vision problems, ringing in the ears, and shoulder pain. Complications may include vision loss. Risk factors include being overweight or a recent increase in weight. Tetracycline may also trigger the condition. Diagnosis is based on symptoms and a high opening pressure found during a lumbar puncture with no specific cause found on a brain scan. Previous studies from investigators at the University of Birmingham (United Kingdom) demonstrated that IIH also featured metabolic disturbances.

In the current study, the investigators compared women aged 18-55 years with active IIH to a sex, age, and body mass index matched control group. IIH participants were identified from neurology and ophthalmology clinics and underwent a prospective intervention to induce disease remission through weight loss with re-evaluation at 12 months.

The investigators evaluated the metabolomic profile in CSF, serum, and urine of patients with IIH compared to control subjects and measured changes in metabolism associated with clinical markers of disease activity and treatment. Clinical assessments included lumbar puncture, headache, eye examination for papilledema, and other visual measurements. Spectra of CSF, serum, and urine metabolites were acquired utilizing proton nuclear magnetic resonance spectroscopy.

Results revealed that urea was lower in IIH (CSF and urine) and correlated with intracranial pressure and headache severity. The lactate:pyruvate ratio was increased in CSF and serum of IIH patients compared to controls and decreased at 12 months. Baseline acetate was higher in IIH, correlated with headache severity and disability and was reduced at 12 months. Ketones 3-hydroxybutyrate and acetoacetate were altered in CSF at baseline in IIH and normalized at 12 months. That these metabolic disturbances were evident in CSF, serum, and urine of IIH patients suggested a pattern of global metabolic dysregulation. Furthermore, altered ketone body metabolites became normalized following therapeutic weight loss.

Senior author Dr. Alex Sinclair, professor of neurology at the University of Birmingham said, “The experiences that patients with IIH have are significant and without being picked up can have serious consequences including sight loss. This is why this research is so important. We are identifying markers that can help to both identify a way to diagnose IIH, as well as provide a much better understanding of the root causes of the condition.

The study was published in the September 8, 2022, online edition of the journal Neurology.

Related Links:
University of Birmingham


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.